Premier Biotech Acquires NTS to Enhance Point-of-Care Drug Screening Services

Premier Biotech has acquired NTS to expand its point-of-care drug screening services. NTS serves over 1,500 facilities in the US, primarily in government and behavioral health end markets. The acquisition strengthens Premier's leadership in these channels and adds new products and services to its portfolio. Premier CEO Matt Michalik said the acquisition marks a pivotal step in the company's growth journey.